MNTN, Inc. Class A Signals Profitable Growth Ahead

MNTN, Inc Class A ((MNTN)) has held its Q1 earnings call. Read on for the main highlights of the call.

MNTN, Inc. Class A’s latest earnings call struck a broadly upbeat tone, as management balanced strong revenue growth, expanding margins, and rapid clinical progress against a handful of manageable headwinds. Executives emphasized that gains in core franchises, improved profitability, and faster‑than‑planned trial enrollment are outweighing softness in minimally invasive ablation and certain international markets.

Revenue Growth Returns to Double Digits

MNTN reported worldwide revenue of $141.2 million for Q1 2026, up 14.3% year over year, or 12.8% on a constant currency basis. U.S. sales climbed 14.9% to $116.2 million, though sequential growth versus Q4 2025 was modest at roughly 1%, underscoring the importance of the anticipated back‑half ramp.

Profitability Nearly Doubles on Adjusted EBITDA

Profitability moved sharply higher, with adjusted EBITDA reaching $17 million, nearly double the level from the prior‑year quarter. Management paired this result with a full‑year adjusted EBITDA outlook of $96 million to $101 million, signaling confidence that operating leverage and discipline will continue to support earnings.

Gross Margins Expand on Mix and Cost Actions

Gross margin rose to 77.4%, an improvement of about 246 basis points compared with 2025 as the company benefited from a richer product mix and cost efficiencies. Management also highlighted a quarter with gross margin around 81%, supported by lower creative and hosting costs, suggesting further upside when favorable mix and cost controls align.

Clinical Trial Momentum Ahead of Schedule

The BOX NOAF randomized clinical trial is progressing faster than expected, with about 300 of 960 patients enrolled since its start in Q4 last year. Management now expects full enrollment around year‑end, nearly a year ahead of the original plan, a timeline that could accelerate evidence generation and future market adoption.

Pain Management Franchise Delivers Standout Growth

Pain management was a major growth engine, delivering a 28% year‑over‑year increase and U.S. sales of $22.4 million, up about 29.5%. The Cryosphere/Cryo Max Pro device accounted for roughly 70% of pain management revenue, underscoring the franchise’s dependence on this platform but also highlighting robust demand.

Open Ablation and Appendage Management Strength

Open ablation and appendage management continued to expand, with worldwide open ablation revenue up about 15% and U.S. sales rising 17.3% to $39.1 million. Appendage management revenue climbed roughly 16% worldwide, including $48.4 million in U.S. sales, where AtriClip Flex Mini represented about 40% of open appendage revenue, reinforcing its role as a key growth driver.

Regulatory Wins and New Product Launches

The company secured CE Mark approval under the EU MDR for AtriClip Flex Mini and Pro Mini, with European launches planned later this year. Management also pointed to multiple new product introductions across the U.S., China, Japan, and Europe, positioning the portfolio for continued expansion and geographic diversification.

International Growth Despite Local Headwinds

International revenue reached $25.0 million, up 11.5% on a reported basis and 3.3% in constant currency, with Europe growing 13.2% to $16.1 million and Asia Pacific and other regions up 8.4% to $8.9 million. Still, management cited uncertainty in the U.K. and weaker distributor activity in parts of Asia as factors that capped upside outside direct markets.

Product Adoption and Competitive Edge

Management highlighted sustained adoption of the Encompass clamp, strong uptake and share gains from AtriClip Flex Mini and Pro Mini, and growing traction for Cryo XD therapy. Executives argued that this differentiated innovation is enabling market share gains across key cardiac and pain segments, reinforcing the company’s competitive moat.

Weakness in Minimally Invasive Ablation

A notable soft spot was minimally invasive ablation, where U.S. sales declined roughly 25% year over year to $6.4 million and the franchise was described as facing headwinds. These pressures, coupled with lower hybrid AF therapy volumes in parts of the cardiac portfolio, represent ongoing challenges that the company must offset elsewhere.

Deliberate Throttling and Sales Ramp Time

Management acknowledged that sequential revenue growth was only about 1% and noted deliberate throttling of onboarding for certain smaller customer segments to preserve attractive acquisition economics. The company also flagged that recent senior hires and sales team expansions will require time to reach full productivity, implying a lag before these investments translate into stronger top‑line gains.

Guidance Points to Back‑Half Acceleration

Looking ahead, MNTN guided Q2 revenue to $81 million to $83 million, implying about 20% year‑over‑year growth at the midpoint, and full‑year revenue of $347 million to $357 million, or roughly 24% growth. Combined with an adjusted EBITDA outlook of $96 million to $101 million and faster BOX NOAF enrollment plus upcoming European launches, management is signaling confidence in a meaningful acceleration in the second half of the year.

MNTN’s earnings call painted a picture of a company leaning into growth while managing selective pressure points, with strong franchises in pain management, open ablation, and appendage management offsetting weakness in minimally invasive ablation and certain overseas markets. With margins expanding, clinical milestones pulling forward, and guidance calling for faster growth later in the year, investors will be watching execution on sales ramp‑up and product launches as key catalysts.